We report a patient who underwent allogeneic haematopoietic stem cell transplantation (HSCT) and donor lymphocyte infusion (DLI), and later developed acute hepatic failure followed by progressive chronic sclerodermatous graft-versus-host disease (GVHD).
/l) on day þ 21. AML relapse occurred 5 months after HSCT, and CyA was discontinued. The disease was resistant to three courses of chemotherapy and only Ara-C by continuous infusion for 20 days was effective. At the beginning of May 2003, the patient received the first DLI at 2.5 Â 10 7 /kg CD3. After 1 month, complete chimaerism was observed in bone marrow and peripheral blood. On day þ 20 after DLI, the patient developed a grade III acute GVHD involving the skin and liver, which was treated with methylprednisolone, tapered after 3 weeks. A second DLI with 2.5 Â 10 7 /kg CD3 was given at the end of July 2003, when the patient did not show any sign of GVHD and was off immunosuppression. On day þ 41, chronic GVHD with mouth and liver involvement developed. This was confirmed by liver biopsy, which also showed grade IV haemosiderosis (Searle grading). Liver function tests showed ALP 312 IU/l, g-GTP 158 IU/l, AST 144 IU/l and ALT 198 IU/l. Total bilirubin, albumin, prothrombin time and cholinesterase were normal ( Table 1) . The IgG serum level was 1521 mg/dl, and hepatitis A, B and C markers were negative. CMV antigenaemia test and RT-PCR for serum HCV, HBV, EBV, HH6, VZV and HSV were negative. The titer of anti-nuclear antibody was 1:80. Other autoimmune markers were negative. Chronic GVHD involving the skin, with areas of hypo-and hyperpigmentation in the back and in the abdomen, developed on day þ 71 and was not treated. At 105 days after the second DLI, the patient developed oedema of the extremities, ascites and pleural effusion, with decreased levels of albumin (24 g/l) and cholinesterasis (2721 IU/l) and increased prothrombin time (40 s). Transaminases and cholestatic enzymes were stable, except for an increase of ALP (420 U/l); total bilirubin remained normal. RT-PCR for serum HCV, HBV, EBV, HH6, VZV and HSV, and CMV antigenaemia test were negative. The levels of gamma-globulin (IgG 2069 mg/dl, polyclonal) and anti-nuclear antibody (1:2560) increased. Echography and Doppler sonography showed ascites without any other alteration. Liver biopsy was repeated but it did not confirm or exclude liver GVHD because of the inadequate sample. Therapy with albumin and intravenous (i.v.) diuretics was started. Sclerodermatous changes in the forearms and lower legs became evident as the oedema diminished. CyA was given at a dose of 1-2 mg/kg/day orally. Liver function normalized in 3 weeks with resolution of ascites, oedema and pleural effusion. Scleroderma remained stable until day þ 145 after the second DLI, when it involved the arms, legs, thorax and abdomen. Diffuse joint contractures developed. Scleroderma with progression of joint contractures did not improve after an increase in CyA dose (3-5 mg/kg/day), addition of prednisone (1-2 mg/kg/ day) and weekly i.v. methotrexate (10 mg/m 2 ). The patient lost the mobility of the extremities and died because of respiratory failure due to CMV pneumonia while he was in persistent second complete remission of AML.
DLI is a therapeutic option for haematologic disease relapsing after conventional allogeneic HSCT as well as a therapeutic tool in nonmyeloablative transplantation. GVHD after DLI often has an unusual clinical course, intermediate between chronic and acute GVHD, and a poor prognosis. [1] [2] [3] Unusual presentations of liver GVHD, such as the hepatitic variant or autoimmune hepatitis, have been reported in literature. [3] [4] [5] They can occur during the tapering of immunosuppressive therapy or off therapy. 3, 5 The hepatitic variant seems to be more frequent after DLI than the classical cholestatic variant. 3 Chronic GVHD rarely causes hepatic failure, which occurs only in longterm survivors after the development of cirrhosis. 4 Our patient had histologically proven liver chronic GVHD 41 days after DLI and sudden hepatic failure 105 days after DLI. Transaminase levels were slightly increased, which is atypical for acute hepatitis. However, there were some typical signs of autoimmune hepatitis such as the presence of anti-nuclear autoantibodies and an increase of IgG, although the histology was not conclusive. An autoimmune-like reaction during the course of chronic GVHD was probably directed to the liver, which was damaged by chemotherapy and haemosiderosis, causing hepatic failure without previous acute hepatitis.
Another interesting point is that the immunosuppressive therapy led to resolution of the hepatic failure in a relatively short time but was not efficacious against scleroderma. Hepatic GVHD and scleroderma could have had different but correlated immunopathogenesis. There is no unique theory to explain the immunopathogenesis of chronic GVHD. [6] [7] [8] Clinical data and experimental models have demonstrated that chronic GVHD has an imbalance in the immune response toward Th1 type. 6 A Th2 polarization with autoimmune aspects has been observed in some cases. [5] [6] [7] [8] In our case, a Th2-type reaction could have been the trigger for hepatic and sclerodermic flare or a Th2 response could have been followed by the shift toward a Th1 response. The first immunosuppressive therapy could have stopped the Th2 reaction but not Th1 and/or the flow of cytokines and chemokines, which activated fibrosis through TGF-b.
The administration of a second DLI when the patient was in complete remission after acute GVHD is a matter of opinion. The efficacy of DLI in relapsed acute leukaemias (ALs) is not so evident as in CML relapsed in chronic phase.
9, 10 Raiola et al 10 demonstrated that the response rate of ALs to DLI in complete remission after chemotherapy was 75% and the disease-free survival (DFS) was 48%. In resistant disease not responding to chemotherapy, the response rate and DFS were both 0%. 10 No correlation was demonstrated between response and total number of CD3 þ cells infused, or duration of DLI treatment, even if bulk doses of DLI were administered to patients with highrisk AL. 9, 10 In our case, the disease was resistant to three lines of therapy and remission was achieved only with another course of chemotherapy. A long-lasting response to DLI would have been closer to 0 than 48%, and thus we decided to risk severe GVHD rather than another relapse. It is still difficult to resolve the dilemma between risk of severe GVHD and benefit of graft-versus-leukaemia.
Moreover, the characteristic course of GVHD after DLI will require a sudden restoring of full-dose immunosuppressive therapy, especially in the presence of scleroderma. On the other hand, starting immunosuppressive therapy is often delayed to reduce the risk of relapse. Decisions about which cases require immunosuppressive therapy and when it should be started are still open questions. Answers should come from better definitions of prognosis related to the different clinical courses and immunologic reactions involved in chronic GVHD. At the time of the second DLI, day 0, the patient did not show signs of GVHD and was off immunosuppression; day +41 ¼ onset of chronic GVHD; liver+mouth, first liver biopsy; day +105 ¼ hepatic failure, ascites, diffuse oedema, second liver biopsy; day +136 ¼ resolution of hepatic failure, ascites and oedema, and onset of sclerodermatous changes; day +145 ¼ progression of scleroderma.
